Possible role of telomerase and sFas in pathogenesis of various bladder lesions associated with schistosomiasis

Clinical Biochemistry

Volumn 42, Issue 9, 2009, Pages 864-872

  Shaker, Olfat G ^a   Hammam, Olfat ^b   Salehd, Abeya ^c   El Leithy, Tarek ^d   Wishahi, Mohamed ^d  

^a CAIRO UNIVERSITY   (Egypt)

^b Theodor Bilharz Research Institute   (Egypt)

^c THEODOR BILHARZ RESEARCH INSTITUTE   (Egypt)

^d Egypt   (Egypt)

Author keywords

SCC; Schistosomiasis; sFas; Telomerase reverse transcriptase (hTERT) enzyme; TRAP; Urothelial carcinoma

Indexed keywords

FAS ANTIGEN; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; THROMBIN RECEPTOR ACTIVATING PEPTIDE;

ADULT; ARTICLE; BLADDER CANCER; BLOOD SAMPLING; CANCER GRADING; CANCER STAGING; CONTROL GROUP; CONTROLLED STUDY; CYSTITIS; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHISTOSOMIASIS; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; ANTIGENS, CD95; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; SCHISTOSOMIASIS; TELOMERASE; URINARY BLADDER NEOPLASMS;

EID: 67349106074     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2008.12.025     Document Type: Article

References (37)

1. El Bolkainy M.N., Mokhtar N.M., Ghoneim M.A., and Hussein M.H. The impact of schistosomiasis on the pathology of bladder carcinoma. Cancer 48 (1981) 2643-2648
2. Rosin M.P., Anwar W.A., and Ward A.J. Inflammation, chromosomal instability and cancer; the schistosomaisis model. Cancer Res. 54 (1994) 1929s-1933s
3. Kitinya J.N., Lauren P.A., Eshleman L.J., Paljarvi L., and Tanaka K. The incidence of squamous and transitional cell carcinomas of the urinary bladder in Northern Tanzania in areas of high and low levels of endemic schistosoma haematobium infection. Trans. R. Soc. Trop. Med. Hyg. 8 (1986) 935-939
4. Ellison V., and Stillman B. Biochemical characterization of DNA damage checkpoint complexes: clamp loader and clamp complexes with specificity for 5′ recessed DNA. PLoS Biol. 1 (2003) E33-E40
5. Mondello C., and Scovassi A. Telomeres, telomerase and apoptosis. Biochem. Cell. Biol. 4 (2004) 498-507
6. Harley C. Telomere loss: mitotic clock or genetic time bomb. Mutat. Res. 256 (1991) 271-282
7. Artandi S.E., and Attardi L.D. Pathways connecting telomeres and p53 in senescence, apoptosis, and cancer. Biochem. Biophys. Res. Commun. 331 (2005) 881-890
8. Shay J.W. Meeting report: the role of telomeres and telomerase in cancer. Cancer Res. 65 (2005) 3513-3517
9. Urquidi V., Tarin D., and Goodison S. Role of telomerase in cell senescence and oncogenesis. Annu. Rev. Med. 51 (2000) 65-79
10. Wu Y.Y., Hruszkewycz A.M., Delgado R.M., et al. Limitations on the quantitative determination of telomerase activity by the electrophoretic and ELISA based TRAP assays. Clin. Chim. Acta 293 (2000) 199-1912
11. Sugino T., Yoshida K., Bolodeoku J., Tarin D., and Goodison S. Telomerase activity and its inhibition in benign and malignant breast lesions. J. Pathol. 183 (1997) 57-61
12. Fan Y., Liu Z., Fang X., et al. Differential expression of full-length telomerase reverse transcriptase mRNA and telomerase activity between normal and malignant renal tissues. Clin. Cancer Res. 11 12 (2005) 4331-4337
13. Khalbuss W., and Goodison S. Immunohistochemical detection of hTERT in urothelial lesions: a potential adjunct to urine cytology. J. Cytol. 3 (2006) 18-25
14. The European Cancer Conference-Barcelona Spain-European Cancer Organization. Apoptosis in bladder and prostate cancer: the role of FAS and FASL polymorphisms. 2007, P#536.
15. Konno R., Takano T., Sato S., and Yajima A. Serum soluble Fas level as a prognostic factor in patients with gynecological malignancies. Clin. Cancer Res. 6 (2000) 3576-3580
16. Chopin D., Barei-Moivi R., Maille P., et al. Human urinary bladder transitional cell carcinomas acquire functional Fas ligand during tumour progression. Am. J. Pathol. 162 4 (2003) 1139-1149 (April)
17. Mizutani Y., Yoshida O., Kawa A., and Boavida B Miki T. Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer. Cancer Biother. Radiopharm. 17 5 (2002) 537-563 (Oct)
18. Mostofi F., Sobin L., and Torloni H. Histological typing of urinary bladder tumours. International classification of tumors Vol. 10 (1973), World Health Organization, Geneva
19. In: Hermanek P., and Sobin L. (Eds). TNM classification of malignant tumours. 4th ed (1992), Springer-Verlag, Berlin 309-313
20. Bradford M.M. A rapid and sensitive method for the microgram quantitation of protein utilizing the principle of protein dye binding. Anal. Biochem. 72 (1976) 248-254
21. Kim N.W., Piatyszek M., Prowse K., et al. Specific association of human telomerase activity with immortal cells and cancer. Science (Wash. D.C.) 266 (1994) 2011-2015
22. Iczkowski K.A., Pantazis C.G., McGregor D.H., Wu Y., and Tawfik O.W. Telomerase reverse transcriptase subunit immunoreactivity: a marker for high-grade prostate carcinoma. Cancer 95 (2002) 2487-2493
23. Erdem E., Dikmen G., Atsu N., Dogan P., and Ozen H. Telomerase activity in diagnosis of bladder cancer. Scand. J. Urol. Nephrol. 37 (2003) 205-209
24. Yoshida K. Telomerase activity in gastrointestinal, bladder and breast carcinomas and their clinical applications. Nippon Rinsho 62 (2004) 1368-1376
25. Lee D., Yang S., Hong S., Chung B., and Kim I. Telomerase: a potential marker of bladder transitional cell carcinoma in bladder washes. Clin. Cancer Res. 4 (1998) 535-538
26. Abd El Gawad I.A., Moussa H.S., Nasr M.I., et al. Comparative Study of NMP-22, telomerase, and BTA in the detection of bladder cancer. J. Egypt. Natl. Cancer Inst. 17 (2005) 193-202
27. Abdel-Salam I.M., Khaled H.M., Gaballah H.E., Mansour O.M., Kassem H.A., and Metwaly A.M. Telomerase activity in bilharzial bladder cancer. Prognostic implications. Urol. Oncol. 6 (2001) 149-153
28. Hohaus S., Cavallo S., and Bellacosa A. Telomerase activity in human laryngeal squamous cell carcinoma. Clin. Cancer Res. 2 (1996) 1895-1900
29. Hiyama E., Yokoyama T., and Tatsumoto N. Telomerase activity in gastric cancer. Cancer Res. 55 (1995) 3258-3262
30. Reddel R., and Bryan T. Alternative lengthening of telomers: dangerous road less traveled. Lancet 361 (2003) 1840-1841
31. Morsi M.I., Youssef A.I., Hassouna M.E., El-Sedafi A.S., Ghazal A.A., and Zaher E.R. Telomerase activity, cytokeratin 20 and cytokeratin 19 in urine cells of bladder cancer patients. J. Egypt. Natl. Cancer Inst. 18 (2006) 82-93
32. Tahara H., Kuniyasu H., and Yokozaki H. Telomerase activity in preneoplastic and neoplastic gastric & colorectal lesions. Clin. Cancer Res. 1 (1995) 1245-1251
33. Dettlaff-Pokora A., Matuszewski M., and Schlichtholz B. Telomerase activity in urine sediments as a tool for noninvasive detection of bladder cancer. Cancer Lett. 10 222 (2005) 83-88
34. Asaad N., Abd El-Wahed M., and Mohamed A. Human telomerase reverse transcriptase (hTRET) gene expression in thyroid carcinoma: diagnostic and prognostic role. J. Egypt. Natl. Cancer Inst. 18 (2006) 8-16
35. Mavrommatis J., Mylona E., Gakiopoulou H., et al. Nuclear hTERT immunohistochemical expression is associated with survival of patients with urothelial bladder cancer. Anticancer Res. 25 (2005) 3109-3116
36. Yan P., Benhattar J., Seelentag W., Stehle J.C., and Bosman F.T. Immunohistochemical localization of hTERT protein in human tissues. Histochem. Cell Biol. 121 (2004) 391-397
37. Perianayagam M., Murray S., Balakrishnan V., et al. Serum soluble Fas (CD (%) and Fas ligand profiles in chronic kidney failure. J. Lab. Clin. Med. 136 4 (2000) 320-327 (Oct)